Beschreibung:
<jats:sec><jats:title>Objective</jats:title><jats:p> Oxaliplatin, a key part of the standard regimen for colorectal cancer in Western countries, has become available in Japan. In a hemodialysis patient with cecal cancer, we investigated the efficacy, safety, pharmacokinetics, and dialysability of oxaliplatin. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> A 65-year-old man who had cecal cancer was treated with oxaliplatin (40 mg/m<jats:sup>2</jats:sup>) and l-leucovorin(l-LV) (200 mg/m<jats:sup>2</jats:sup>), which were administered simultaneously over 120 min via the side and main arms of a Y-tube, respectively. Then 5-FU (400 mg/m<jats:sup>2</jats:sup>) was administered rapidly via the side tube, followed by 5-FU (2,000 mg/m<jats:sup>2</jats:sup>) over 46 hours via the main tube. The patient had chronic renal failure due to diabetic nephropathy and hemodialysis was performed 3 times a week. Blood samples were collected from the dialyzer before and after each hemodialysis session to examine platinum clearance. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> The patient received 3 courses of oxaliplatin before he died of cancer. During hemodialysis, the platinum level fell from 0.32 μg/mL to 0.15 μg/mL. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Since patients with renal failure have various associated disorders and oxaliplatin has a long half-life, it is necessary to obtain more pharmacokinetic data to investigate its accumulation and dialysability during long-term treatment. Such data will assist in treating the rapidly increasing number of hemodialysis patients with colorectal cancer. </jats:p></jats:sec>